Qiagen N.V. (QGEN)
NYSE: QGEN · Real-Time Price · USD
45.28
+0.38 (0.85%)
Jun 3, 2025, 4:00 PM - Market closed
Qiagen Employees
Qiagen had 5,967 employees as of December 31, 2023. The number of employees decreased by 211 or -3.42% compared to the previous year.
Employees
5,967
Change (1Y)
-211
Growth (1Y)
-3.42%
Revenue / Employee
$335,658
Profits / Employee
$15,699
Market Cap
9.81B
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 5,967 | -211 | -3.42% |
Dec 31, 2022 | 6,178 | 150 | 2.49% |
Dec 31, 2021 | 6,028 | 418 | 7.45% |
Dec 31, 2020 | 5,610 | 514 | 10.09% |
Dec 31, 2019 | 5,096 | 144 | 2.91% |
Dec 31, 2018 | 4,952 | 264 | 5.63% |
Dec 31, 2017 | 4,688 | 4 | 0.09% |
Dec 31, 2016 | 4,684 | 125 | 2.74% |
Dec 31, 2015 | 4,559 | 220 | 5.07% |
Dec 31, 2014 | 4,339 | 324 | 8.07% |
Dec 31, 2013 | 4,015 | 16 | 0.40% |
Dec 31, 2012 | 3,999 | 61 | 1.55% |
Dec 31, 2011 | 3,938 | 351 | 9.79% |
Dec 31, 2010 | 3,587 | 92 | 2.63% |
Dec 31, 2009 | 3,495 | 454 | 14.93% |
Dec 31, 2008 | 3,041 | 379 | 14.24% |
Dec 31, 2007 | 2,662 | 708 | 36.23% |
Dec 31, 2006 | 1,954 | 365 | 22.97% |
Dec 31, 2005 | 1,589 | 267 | 20.20% |
Dec 31, 2004 | 1,322 | -231 | -14.87% |
Dec 31, 2003 | 1,553 | -98 | -5.94% |
Dec 31, 2002 | 1,651 | 94 | 6.04% |
Dec 31, 2001 | 1,557 | 242 | 18.40% |
Dec 31, 2000 | 1,315 | - | - |
Sources: Annual number of employees according to filings submitted to the U.S. Securities and Exchange Commission (SEC). Data is also manually gathered from company press releases, IPO filings, and other official sources.
Related Stocks
Company Name | Employees |
---|---|
UnitedHealth Group | 400,000 |
Johnson & Johnson | 138,100 |
Abbott Laboratories | 114,000 |
AstraZeneca | 94,300 |
Novo Nordisk | 77,349 |
Novartis AG | 75,883 |
Merck & Co. | 75,000 |
AbbVie | 55,000 |
QGEN News
- 1 day ago - QIAGEN expands portfolio for minimal residual disease (MRD) testing in oncology with new strategic partnerships - Business Wire
- 1 day ago - Foresight Diagnostics and QIAGEN Announce Strategic Partnership to Advance Development of Companion Diagnostic Kits for Lymphoma - PRNewsWire
- 12 days ago - QIAGEN expands digital PCR oncology research portfolio through partnership with ID Solutions - Business Wire
- 19 days ago - Qiagen Beats Earnings, But Its Expensive Valuation Caps Upside Potential - Seeking Alpha
- 22 days ago - QIAGEN enhances leading clinical genomics portfolio with acquisition of Genoox AI-powered software - Business Wire
- 26 days ago - Qiagen N.V. (QGEN) Q1 2025 Earnings Call Transcript - Seeking Alpha
- 27 days ago - QIAGEN announces plans for transition in leadership of Supervisory Board - Business Wire
- 27 days ago - QIAGEN delivers solid Q1 2025 results exceeding outlook; will seek shareholder approval to initiate a dividend and new $500 mn repurchase - Business Wire